uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022
17 nov. 2022 07h05 HE
|
uniQure Inc.
~ Event to be Webcast Live on uniQure’s Corporate Website at 8:30 a.m. EST ~ LEXINGTON, Ma. and AMSTERDAM, Nov. 17, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy...
Cyclacel Hosting Research & Development Day
24 oct. 2022 09h15 HE
|
Cyclacel
-Program Update on its CDK2/9 Inhibitor, Oral Fadraciclib, and Oral PLK1 Inhibitor, CYC140, for the Treatment of Advanced Solid Tumors and Lymphoma- -Monday, October 31st @ 10 am ET- ...
Praxis Precision Medicines to Host Epilepsy Day on April 27, 2022
13 avr. 2022 08h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Silence Therapeutics to Host R&D Day on October 21, 2021
07 oct. 2021 07h00 HE
|
Silence Therapeutics plc
Silence Therapeutics to Host R&D Day on October 21, 2021 7 October 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery,...
Travere Therapeutics to Host Virtual R&D Day on Wednesday, December 9, 2020
01 déc. 2020 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that the Company will host a virtual R&D Day on Wednesday, December 9, 2020 at 12:00 p.m. ET to...
Surface Oncology Announces Filing of IND for CD39 Targeted Antibody Candidate, SRF617, at Inaugural R&D Day
18 nov. 2019 06h30 HE
|
Surface Oncology, Inc.
Details clinical plans for phase 1/1b clinical studies of SRF617 and SRF388 in patients with advanced solid tumors Shares preclinical data for new, CD112R targeted antibody candidate, SRF813, and its...
Summit Therapeutics to Host R&D Day 7 October 2019
25 sept. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Host R&D Day 7 October 2019 Oxford, UK, and Cambridge, MA, US, 25 September 2019 – Summit Therapeutics plc...
Autolus Therapeutics Unveils Expanded Next Generation Technology and Pipeline and Provides Key Update on AUTO3 Program in Pediatric ALL at R&D Day
26 mars 2019 06h00 HE
|
Autolus Therapeutics plc
LONDON, March 26, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next generation programmed T cell therapies for the...
ObsEva R&D Day Showcases Multiple Women’s Health Programs and Outlines Plans for Transition to Commercial Operations
07 déc. 2018 12h12 HE
|
ObsEva SA
Clinical Trial Data and Regulatory Progress on Lead Programs Targeting IVF, Endometriosis, and Uterine Fibroids to Transform Company in 2019 GENEVA, Switzerland and BOSTON, Mass. (December...
ObsEva SA to Host R&D Investor Day December 7, 2018
29 nov. 2018 01h30 HE
|
ObsEva SA
Geneva, Switzerland and Boston, MA – November 29, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics...